At the news
? BEARISHIMPACT 7/10 8-K filed May 8, 2026 at 16:20 ET
Longeveron disclosed that the FDA rejected the primary endpoint (RVEF) of its Phase 2b ELPIS II trial for HLHS, and the FDA no longer considers the trial 'pivotal.' Top-line results are still expected in August 2026. This is a material regulatory setback for a micro-cap biotech with no approved products.
- FDA stated primary endpoint (RVEF) is not appropriate to demonstrate efficacy
- FDA no longer refers to ELPIS II as a pivotal trial
- FDA willing to discuss results after trial completion
- Top-line results expected August 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access